![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C11H13NNa2O7S2 |
Molar mass | 381.32 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Disufenton sodium (Cerovive, OKN-007, NXY-059, HPN-07) [1] is a free radical trapping nitrone-based antioxidant compound that has been under development for several medical conditions. [2] [3]
Disufenton sodium is the disulfonyl derivative of the neuroprotective nitrone spin trap phenylbutylnitrone or "PBN". PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH (AKA, NtBHA) and its parent spin-trap MNP.
Disufenton sodium was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial [4] [5] called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance". [4] AstraZeneca then terminated the development programme. [6]
Disufenton sodium has been researched as a potential treatment for use in brain tumors and cancers, including diffuse intrinsic pontine glioma (DIPG) [7] [8] and glioblastoma. [9] [10]
A compound (NHPN-1010) containing a combination of disufenton sodium and acetylcysteine has been researched as a potential treatment for tinnitus and hearing loss. [11] [12] [13] [14]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C11H13NNa2O7S2 |
Molar mass | 381.32 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Disufenton sodium (Cerovive, OKN-007, NXY-059, HPN-07) [1] is a free radical trapping nitrone-based antioxidant compound that has been under development for several medical conditions. [2] [3]
Disufenton sodium is the disulfonyl derivative of the neuroprotective nitrone spin trap phenylbutylnitrone or "PBN". PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH (AKA, NtBHA) and its parent spin-trap MNP.
Disufenton sodium was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial [4] [5] called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance". [4] AstraZeneca then terminated the development programme. [6]
Disufenton sodium has been researched as a potential treatment for use in brain tumors and cancers, including diffuse intrinsic pontine glioma (DIPG) [7] [8] and glioblastoma. [9] [10]
A compound (NHPN-1010) containing a combination of disufenton sodium and acetylcysteine has been researched as a potential treatment for tinnitus and hearing loss. [11] [12] [13] [14]